Funding profile · At home diagnostics
Examedi
One Cayman holding company sold $22,499,000 of stock in 2022 and has filed nothing since. Two small Sydecar vehicles carried part of a 2026 down round.
$22.5MSold to 41 investors, Form D filed Jul 8, 2022
$5.50MGap between the filing and the $17M announced Series A
$174KCombined 2026 SPV money, from 45 investors
$17MValuation at the Nov 2025 round, reported as about 80% below peak
Data as of September 22, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2021 | Platanus Ventures, then Y Combinator Summer 2021 | Not disclosed | Platanus Ventures; Y Combinator | YC and press |
| Sep 2021 | Seed, as first reported | $2.7M | 8VC, Quiet Capital, Goodwater Capital | Independent |
| Feb 2022 | Seed, as restated | US$3.9M total raised | Adds Nexus Partners, Platanus Ventures, Chilean family offices | Independent |
| Jun 2022 | Seed, as restated by the company | $3.5M | Not itemised | Company release |
| May to Jul 2022 | Series A | $17M announced; $22,499,000 sold per the filing | General Catalyst (lead); Thomaz Srougi, Sebastián Mejía, Jamie Karraker | Form D and release |
| Nov 2025 | Priced round, down | US$750K at a US$17M valuation | Platanus (lead) with sitting board members including Patrick Kiblisky; General Catalyst exits | Independent |
| Feb 2026 | SPV: Examedi B a Series of CGF2021 LLC | $129,144 | 20 investors; administered by Sydecar | Form D |
| Mar 2026 | SPV: Examedi A Nov 2025 a Series of CGF2021 LLC | $44,988 | 25 investors; administered by Sydecar | Form D |
What the filings show
Examedi Holdings Ltd · Form D · filed Jul 8, 2022
- First sale
- May 11, 2022
- Offered
- $22,499,000 equity
- Sold
- $22,499,000 · $0 remaining
- Investors
- 41 · average about $548,756
- Exemption
- Rule 506(b)
- Issuer
- Cayman Islands company, incorporated 2021, address in Las Condes, Santiago
- Related persons
- Eun Bin Lee (director); Andres Kemeny (director); Juan Pablo Zepeda (director), all Santiago
- Filing
- SEC EDGAR, CIK 0001937324
Examedi B a Series of CGF2021 LLC · Form D · filed Feb 13, 2026
- First sale
- Feb 11, 2026
- Type
- Pooled investment fund (single company vehicle), Delaware, formed 2026
- Sold
- $129,144 of $129,144
- Investors
- 20 · average about $6,457
- Exemptions
- Rule 506(b); Investment Company Act 3(c)(1)
- Related persons
- Sydecar LLC (administrator); Brett Sagan (officer of the administrator)
- Filing
- SEC EDGAR, CIK 0002102013
Examedi A Nov 2025 a Series of CGF2021 LLC · Form D · filed Mar 17, 2026
- First sale
- Mar 13, 2026
- Type
- Pooled investment fund (single company vehicle), Delaware, formed 2026
- Sold
- $44,988 of $44,988
- Investors
- 25 · average about $1,800
- Exemptions
- Rule 506(b); Investment Company Act 3(c)(1)
- Related persons
- Sydecar LLC (administrator); Brett Sagan (officer of the administrator)
- Filing
- SEC EDGAR, CIK 0002102012
Reading the filings
- The filing is $5.5 million bigger than the press release.The Series A was announced on June 22, 2022 at $17 million. The Form D filed on July 8 reports $22,499,000 sold, nothing remaining, first sale May 11, 2022. That is $5,499,000 more, and more than any seed figure published for this company: $2.7 million, US$3.9 million or $3.5 million. Earlier instruments converting into the same priced offering would explain it. The filing does not say so.
- The cheque size is institutional.$22,499,000 across 41 investors averages about $548,756. That is a lead fund, a handful of co-investors and a set of named angels, not a crowd.
- The money sits offshore, the people do not.The issuer is a Cayman Islands company formed in 2021. Its business address and all three listed directors are in Las Condes, Santiago. No US operating entity for Examedi appears in EDGAR at all.
- The 2026 vehicles are small, and they arrived late.Together the two Sydecar series raised $174,132 from 45 investors. One of them is named for November 2025, the month the down round was reported, yet its first sale was March 13, 2026, four months later. The other, lettered B, sold first, on February 11, 2026. Both report $5,500 of proceeds going to officers or directors, the administrator fee.
- The vehicles cover less than a quarter of the reported round.$174,132 against the US$750,000 reported in November 2025 is about 23%. The rest produced no Form D, which happens when the remainder comes from existing preferred holders under an earlier authorisation, or when the issuer relies on Section 4(a)(2).
- Four years of silence under the company’s own number.Examedi Holdings Ltd has filed nothing with the SEC since July 2022. The 2025 round, the General Catalyst exit and the valuation reset all happened without a filing under CIK 0001937324.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Revenue | US$3.5 million in 2025, below the US$4 million projected that November. About US$3.8 million targeted for 2026. | Independent |
| Profitability | Mexico reached break even in October 2025. Company wide operating profitability reported as expected by the end of 2026. | Independent |
| Mix | Mexican B2B growing above 60% a year; Chilean consumer business described as stabilised and slower. | Independent |
| Cost base | Headcount cut from about 160 to about 25; gross margins reported up 40%. | Independent |
| Contracts | Clínica Alemana, Imalab, Isapre Nueva Masvida, Clínica Bupa Antofagasta, Caja Los Andes, Laboratorios Chopo in Mexico. | Independent |
| Licensure | No clinical laboratory authorisation in Examedi’s own name found in Chile or Mexico. The partner laboratories hold it. | Not found |
| Governance | Board created in late 2024. By August 2026 no founder remained in the operation. | Independent |
What to watch
- A Form D, or an amendment, under Examedi Holdings Ltd for the November 2025 round. None has appeared.
- Further Sydecar series, which would show the round still filling in 2026.
- Whether operating profitability lands by the end of 2026 as reported.
- The handover to Nicolás Pino, with the last founder leaving.
- Any health authority authorisation in Examedi’s own name.
The Examedi story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordForm D, Examedi Holdings Ltd, CIK 0001937324
- Public recordForm D, Examedi B a Series of CGF2021 LLC, CIK 0002102013
- Public recordForm D, Examedi A Nov 2025 a Series of CGF2021 LLC, CIK 0002102012
- IndependentExamedi tras la cirugía: nuevo CEO, sin fundadores y a meses de la rentabilidad
- IndependentExamedi levanta US$750 mil y alcanza punto de equilibrio en México
- IndependentExamedi raises $750K in a round led by Platanus
- IndependentCirugía en Examedi: salen Ian Lee y otros dos fundadores
- IndependentChilena Examedi levanta US$17 millones en Serie A liderada por General Catalyst
- IndependentThe 11-slide presentation that sold General Catalyst
- IndependentChilean health marketplace Examedi raises $2.7M to grow internationally
- CompanyExamedi raises $17M in Series A funding to improve LATAM healthcare
Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Examedi. This page is not an offer to sell or a recommendation to buy any security.